Uno studio per valutare la sicurezza e la farmacocinetica di AZD7760 negli adulti sani (Fase I) e negli adulti con malattia renale allo stadio terminale in emodialisi con un catetere venoso centrale (Fase IIa) (PEAK)
Uno studio di fase I/IIa randomizzato, in doppio cieco, controllato con placebo per valutare la sicurezza e la farmacocinetica dell'AZD7760 in partecipanti sani e in pazienti con malattia renale allo stadio terminale sottoposti a emodialisi attraverso un catetere venoso centrale
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
In the Phase I portion of the study, participants will be randomized to receive one of 3 dosages of AZD7760 or placebo as a single intravenous infusion.
Study details include:
- A 28-day Screening Period.
- A Dosing Period of 3 days in which a single intravenous infusion will be given on Day 1.
- A Follow-up Period of 12 months from the time of administration of the study intervention.
In the Phase IIa portion of the study, participants will be randomized to receive either AZD7760 or placebo as 2 intravenous infusions given 3 months apart.
Study details include:
- A 28-day Screening Period.
- A Dosing Period in which 2 intravenous infusions will be given 3 months apart (Day 1 and Day 91).
- A Follow-up Period of 12 months after the last administration of the study intervention on Day 91.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Alabama
-
Huntsville, Alabama, Stati Uniti, 35805
- Research Site
-
-
California
-
Chula Vista, California, Stati Uniti, 91910
- Research Site
-
Glendale, California, Stati Uniti, 91206
- Research Site
-
Granada Hills, California, Stati Uniti, 91344
- Research Site
-
Los Angeles, California, Stati Uniti, 90027
- Research Site
-
Northridge, California, Stati Uniti, 91324
- Research Site
-
Northridge, California, Stati Uniti, 91325
- Research Site
-
Oxnard, California, Stati Uniti, 93036
- Research Site
-
Riverside, California, Stati Uniti, 92503
- Research Site
-
San Dimas, California, Stati Uniti, 91773
- Research Site
-
Tarzana, California, Stati Uniti, 91356
- Research Site
-
Valencia, California, Stati Uniti, 91355
- Research Site
-
Victorville, California, Stati Uniti, 92392
- Research Site
-
-
Colorado
-
Englewood, Colorado, Stati Uniti, 80110
- Research Site
-
-
Florida
-
Bradenton, Florida, Stati Uniti, 34209
- Research Site
-
Coral Springs, Florida, Stati Uniti, 33071
- Research Site
-
Hollywood, Florida, Stati Uniti, 33024
- Research Site
-
Orlando, Florida, Stati Uniti, 32806
- Research Site
-
Tampa, Florida, Stati Uniti, 33603
- Research Site
-
-
Georgia
-
Lawrenceville, Georgia, Stati Uniti, 30046
- Research Site
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60640
- Research Site
-
Chicago, Illinois, Stati Uniti, 60643
- Research Site
-
-
Iowa
-
Iowa City, Iowa, Stati Uniti, 52242
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40503
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21225
- Research Site
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48202
- Research Site
-
Pontiac, Michigan, Stati Uniti, 48341
- Research Site
-
-
Mississippi
-
Tupelo, Mississippi, Stati Uniti, 38801
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64111
- Research Site
-
-
Nebraska
-
Lincoln, Nebraska, Stati Uniti, 68510
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89128
- Research Site
-
-
New Jersey
-
Jersey City, New Jersey, Stati Uniti, 07305
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87109
- Research Site
-
-
New York
-
Ridgewood, New York, Stati Uniti, 11385
- Research Site
-
-
North Carolina
-
Winston-Salem, North Carolina, Stati Uniti, 27103
- Research Site
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Stati Uniti, 18017
- Research Site
-
-
Texas
-
Beaumont, Texas, Stati Uniti, 77706
- Research Site
-
Dallas, Texas, Stati Uniti, 75246
- Research Site
-
Houston, Texas, Stati Uniti, 77074
- Research Site
-
McAllen, Texas, Stati Uniti, 78503
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Phase I:
- Participant must be 18 to 55 years of age (inclusive), at the time of signing the informed consent.
- Body weight ≥ 45 kilograms (kg) and ≤ 110 kg and Body Mass Index (BMI) within the range ≥ 18.0 to ≤ 30.0 kilograms per square meter (kg/m2) (inclusive) at screening.
- Healthy participants with no clinically significant concomitant diseases or medications (except for those specifically permitted by the protocol) according to medical history, physical examination, screening safety laboratory tests, and screening parameters, as per the judgement of the investigator.
Phase IIa:
-
Participant must be ≥ 18 years of age at the time of signing the informed consent.
-
Participants who meet all of the following disease status requirements:
- Diagnosed with End-stage kidney disease (ESKD).
- Requiring hemodialysis through a tunneled central venous catheter as the primary vascular access for hemodialysis.
- Receiving hemodialysis for treatment of ESKD for at least 60 days before randomization.
- At least 3 previous dialysis sessions using current dialyzer.
- Receiving adequate hemodialysis based on a single-pool Kt/V measurement > 1.2 within the last 30 days.
- No new medications have been added to the participant's regimen in the last 2 weeks prior to dosing. 'New medication' is defined as any medication that has not been prescribed or used by the participant previously (including formulation changes). Medication previously prescribed or used by the participant with dose adjustments is allowed and not considered as new medication for the purpose of this study.
- Not taking long-term systemic antibiotics with activity against S aureus.
Exclusion Criteria:
Phase I:
- Known hypersensitivity to any component of the study intervention
- Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of monoclonal antibodies (mAbs).
- Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injections or venipuncture.
- Aspartate Aminotransferase (AST) or alanine Aminotransferase (ALT) above 1.5 × upper limit of normal (ULN) at screening. Testing may be repeated once at the investigator's discretion.
- Estimated glomerular filtration rate < 90 mL/min/1.73 m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration equation at screening.
- Hemoglobin or platelet count below the lower limit of normal at screening. Testing may be repeated once at the investigator's discretion.
- White blood cell counts outside normal reference ranges unless judged by the investigator to be out of range given the known variation in white blood cell count reference interval by ethnicity. Testing may be repeated once at the investigator's discretion.
- History of malignancy other than treated non-melanoma skin cancers or locally treated cervical cancer in the previous 5 years.
- Any laboratory value in the screening panel that, in the opinion of the investigator, is clinically significant or might confound analysis of study results. Testing may be repeated once at the investigator's discretion.
- Any clinically significant abnormalities on 12-lead electrocardiogram (ECG) at screening, as judged by the investigator.
- Acute (time-limited) illness, including fever ≥ 38 °C (100.4 °F), one day prior to or on day of planned dosing; participants excluded for transient acute illness may be dosed if illness resolves within the 28-day Screening Period or may be rescreened once.
- Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy, including any course of glucocorticoid therapy exceeding 2 weeks of prednisone or equivalent at a dose of 20 mg daily or every other day within 6 months prior to screening.
- Any condition that has the potential to increase clearance of the study intervention (eg, protein loss conditions such as severe enteropathies, or plasmapheresis).
- Blood drawn in excess of a total of 450 milliliters (mL) (1 unit) for any reason within 2 months prior to screening.
- Absence of suitable veins for blood sampling and administration of study intervention.
- Any other condition that would compromise safety of the participants.
- Any condition that, in the opinion of the investigator, might interfere with evaluation of the study intervention or interpretation of participant safety or study results.
Phase IIa:
-
Known hypersensitivity to any component of the study intervention.
-
History of allergic disease or reactions likely to be exacerbated by any component of the study intervention as listed in dose formulation section.
-
Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of mAbs.
-
Hemoglobin < 9 g/dL at screening considered by the investigator to be due to acute condition(s). Testing may be repeated once at the investigator's discretion.
-
Serum albumin of < 3 g/dL at screening considered by the investigator to be due to acute condition(s). Testing may be repeated once at the investigator's discretion.
-
Myocardial infarction, acute coronary syndrome, stroke, seizure, or a thrombotic/thromboembolic event (eg, deep vein thrombosis or pulmonary embolism, but excluding vascular access thrombosis) within 90 days prior to randomization.
-
Known S aureus infection within 90 days of study entry.
-
Known acute viral or bacterial infection or symptoms/signs consistent with such an infection within the 21 days prior to infusion or study intervention. Mild intercurrent viral illness with a temperature of 38.1 °C (100.6 °F) or less does not require exclusion, if in the judgement of the investigator this illness will not interfere with the evaluation of the mAb.
-
Participants with malignancy undergoing chemotherapy.
-
Scheduled date for living donor kidney transplant.
-
Plans to switch to peritoneal dialysis within the primary endpoint time period (181 days).
-
Regarding arteriovenous fistula (AVF) or arteriovenous graft (AVG):
(a) Future AVG or AVG: (i) Participants with central venous catheters currently in use for dialysis, and future plans for AVF or AVG use within 90 days of randomization are not eligible.
(ii) Participants with central venous catheters currently in use for dialysis, and future plans for AVF or AVG placement, but no plans for AVF or AVG use within 90 days of randomization are eligible.
(b) Existing AVG or AVG: (i) Participants with central venous catheters in use for dialysis, but also with an existing AVF or AVG that is not in use and with no future plans for use are eligible.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Phase I: AZD7760 Dose A
Participants will receive a single dose of AZD7760 Dose A intravenously on Day 1. |
Participants will receive AZD7760 as a single intravenous infusion. |
|
Sperimentale: Phase I: AZD7760 Dose B
Participants will receive a single dose of AZD7760 Dose B intravenously on Day 1. |
Participants will receive AZD7760 as a single intravenous infusion. |
|
Sperimentale: Phase I: AZD7760 Dose C
Participants will receive a single dose of AZD7760 Dose C intravenously on Day 1. |
Participants will receive AZD7760 as a single intravenous infusion. |
|
Comparatore placebo: Phase I: Placebo
Participants will receive a single dose of placebo on Day 1. |
Participants will be administered placebo through intravenous infusion. |
|
Sperimentale: Phase IIa: AZD7760 Dose D and Placebo
Participants will receive AZD7760 Dose D and placebo on Day 1 on Day 91. |
Participants will receive AZD7760 as a single intravenous infusion. Participants will be administered placebo through intravenous infusion. |
|
Sperimentale: Phase IIa: AZD7760 Dose E
Participants will receive AZD7760 Dose E on Day 1 and Day 91. |
Participants will receive AZD7760 as a single intravenous infusion. |
|
Comparatore placebo: Phase IIa: Placebo
Participants will receive placebo on Day 1 and on Day 91. |
Participants will be administered placebo through intravenous infusion. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Phase I: Occurence of adverse events (AEs)
Lasso di tempo: Day 1 to Day 181
|
To evaluate the safety of AZD7760 administered as a single intravenous (IV) Dose A, B, or C. |
Day 1 to Day 181
|
|
Phase I: Occurence of medically-attended adverse events (MAAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)
Lasso di tempo: Day 1 to Day 361
|
To evaluate the safety of AZD7760 administered as a single IV Dose A, B, or C. |
Day 1 to Day 361
|
|
Phase IIa: Occurrence of AEs, MAAEs, SAEs, and AESIs
Lasso di tempo: Day 1 to Day 181
|
To evaluate the safety of AZD7760 compared with placebo as:
|
Day 1 to Day 181
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Phase I: Maximum observed plasma (peak) drug concentration (Cmax)
Lasso di tempo: Day 1 to Day 361
|
To characterize the pharmacokinetics (PK) of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Time to reach peak or maximum observed concentration following drug administration (tmax)
Lasso di tempo: Day 1 to Day 361
|
To characterize the PK of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz)
Lasso di tempo: Day 1 to Day 361
|
To characterize the PK of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast)
Lasso di tempo: Day 1 to Day 361
|
To characterize the PK of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Area under plasma concentration-time curve from zero extrapolated to infinity (AUCinf)
Lasso di tempo: Day 1 to Day 361
|
To characterize the PK of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Apparent volume of distribution at steady state (Vss)
Lasso di tempo: Day 1 to Day 361
|
To characterize the PK of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Apparent volume of distribution at the terminal phase (Vz)
Lasso di tempo: Day 1 to Day 361
|
To characterize the PK of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Incidence of ADA
Lasso di tempo: Day 1 to Day 361
|
To evaluate ADA responses to AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase IIa: Cmax
Lasso di tempo: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: tmax
Lasso di tempo: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: t1/2λz
Lasso di tempo: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: AUClast
Lasso di tempo: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: AUCinf
Lasso di tempo: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: Vss
Lasso di tempo: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: Vz
Lasso di tempo: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: Incidence of anti-drug antibodies (ADAs) to AZD7760 in serum
Lasso di tempo: Day 1 to Day 181 and Day 1 to Day 451
|
To evaluate ADA responses to AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: Occurrence of AEs
Lasso di tempo: Day 1 to Day 181
|
To evaluate the safety to Day 181 of AZD7760 administered as:
|
Day 1 to Day 181
|
|
Phase IIa: Occurrence of MAAEs, SAEs, and AESIs
Lasso di tempo: Day 1 to Day 451
|
To evaluate the safety to Day 451 of AZD7760 administered as:
|
Day 1 to Day 451
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Processi patologici
- Malattie urogenitali maschili
- Malattie renali
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattia cronica
- Attributi della malattia
- Infezioni
- Sindrome da risposta infiammatoria sistemica
- Infiammazione
- Insufficienza renale
- Infezioni batteriche Gram-positive
- Infezioni batteriche
- Infezioni batteriche e micosi
- Insufficienza renale cronica
- Condizioni patologiche, segni e sintomi
- Infezioni da stafilococco
- Sepsi
- Insufficienza renale cronica
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- D7480C00001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Periodo di condivisione IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Criteri di accesso alla condivisione IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .